29 August 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Ondine to present new AMR research at ICPIC, Geneva
Ondine Biomedical to present new research on efficacy of photodisinfection against key gram-negative bacteria driving antimicrobial resistance threat
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research on the efficacy of antimicrobial photodynamic therapy, known as photodisinfection, against extensively drug-resistant gram-negative bacteria at the 7th International Consortium on Prevention & Infection Control (ICPIC) taking place in Geneva, from 12-15 September 2023. ICPIC is a leading international conference on the prevention of healthcare-associated infection and the control of antimicrobial resistance around the world.
Antimicrobial resistance (AMR) poses an urgent global public health threat. The US has shown an alarming increase of 35% in AMR Enterobacteriaceae infections[i] and analysis published in The Lancet found that 1.27 million deaths worldwide in 2019 were the direct result of drug-resistant bacterial infections.[ii] Extensively drug-resistant (XDR) bacteria are a particularly concerning category of multidrug-resistant organisms that are proving resistant to almost all or all approved antimicrobial agents.[iii]
Dr. Nicolas Loebel, Ondine's CTO and President, commented:
"Overuse of antibiotics over decades has caused adaptation in many microbes, and we now see multidrug resistance (MDR) evolving into extensive drug resistance (XDR) in bacteria, rendering even the most powerful drugs ineffective. We believe photodisinfection can play a significant role in cost effectively combatting these drug-resistant pathogens and reducing global reliance on antibiotics."
Photodisinfection is an easy-to-use alternative to antibiotics and antifungals, including MDR and XDR strains, because it is highly effective against all types of disease-causing pathogens and, as a non-biological treatment, does not generate resistance.
Ondine's photodisinfection is a patented technology using a proprietary photosensitizer that when illuminated with a specific wavelength of non-thermal red light, causes an oxidative burst that produces reactive oxygen species that are lethal to bacteria, fungi, algae, protozoa and viruses, by utilizing multi-target action mechanisms. Ondine is a previous winner of an ICPIC Innovation Award of Excellence for its clinical and pre-clinical work demonstrating photodisinfection efficacy against numerous SARS-CoV-2 strains.
The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram-Negative Isolates With Novel Antibiotic Resistance Factors", will be presented at ICPIC from 1pm CET on 13 September 2023. A further announcement will be released by the Company concurrent with the start of the presentation at ICPIC.
| Ondine Biomedical Inc. |
|
| Carolyn Cross, CEO | +001 (604) 665 0555 |
|
|
|
| Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| |
|
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
[i] CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2022. doi:https://dx.doi.org/10.15620/cdc:117915
[ii] The Lancet, Volume 399, Issue 10325, P629-655, February 12, 2022 https://doi.org/10.1016/S0140-6736(21)02724-0
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
